Adding chemotherapy and bevacizumab to immunotherapy improves tumor control in a high-risk CRC subset, but this benefit comes ...
First-line zanidatamab plus chemotherapy leads to ‘practice-changing’ PFS and overall survival gains in a phase 3 study of ...
Revolution Medicines surged on AbbVie buyout rumors but pulled back after denial. Learn what's next for RVMD stock and why it ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback